Related Experiment Video

Updated: Aug 16, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Epidermal growth factor inhibition in solid tumours

Apar Kishor Ganti1, Anil Potti

  • 1Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. aganti@unmc.edu

Expert Opinion on Biological Therapy
|August 27, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) is a key target in cancer therapy. Approved treatments include EGFR antibodies and tyrosine kinase inhibitors, with ongoing development of new agents.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is implicated in the development of numerous human cancers.
  • Targeting EGFR offers a promising strategy for anticancer therapy.

Purpose of the Study:

  • To review currently approved therapies targeting EGFR.
  • To present efficacy data for these agents in various human malignancies.
  • To mention emerging EGFR-targeting agents in early development.

Main Methods:

  • Review of approved EGFR-targeting agents: cetuximab (monoclonal antibody), gefitinib, and erlotinib (tyrosine kinase inhibitors).
  • Presentation of clinical efficacy data for these agents across different malignancies.
  • Inclusion of information on novel agents in early developmental stages.

Main Results:

  • Cetuximab, gefitinib, and erlotinib are established EGFR-targeting therapies.
  • Efficacy data demonstrates the clinical utility of these agents in treating various cancers.
  • Several new EGFR-targeting agents are under investigation.

Conclusions:

  • EGFR-targeting therapies, including antibodies and tyrosine kinase inhibitors, are crucial in oncology.
  • Approved agents like cetuximab, gefitinib, and erlotinib show clinical efficacy.
  • Ongoing research into novel agents promises further advancements in EGFR-targeted cancer treatment.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...